A Phase 4 interventional study of Dutasteride (0.5mg) and Placebo in Benign Prostatic Hyperplasia, Postoperative Hemorrhage and Perioperative Hemorrhage Control During Bipolar Transurethral Resection of the Prostate (TURP) in Patients on Anticoagulant or Antiplatelet Therapy, sponsored by Mohamed Mahmoud Dogha. Not yet recruiting at 1 site in Egypt. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Mohamed Mahmoud Dogha · Phase 4, Interventional, and Prevention
A prospective, randomized, double-blinded controlled trial to evaluate the efficacy of a 2-week preoperative and 2-week postoperative course of oral dutasteride (0.5 mg daily) in reducing perioperative blood loss, irrigation requirements, and catheterization time in patients on anticoagulant therapy undergoing bipolar TURP for benign prostatic hyperplasia (BPH).
This prospective double-blinded randomized study was conducted to assess the effect of two-week pretreatment with a 5-alpha reductase inhibitor (5-ARI) dutasteride 0.5 mg orally once daily on perioperative outcomes in patients with benign prostatic hyperplasia (BPH) undergoing bipolar transurethral resection of the prostate (TURP). The study will particularly evaluate its effect on intraoperative and postoperative bleeding, as well as the volume and duration of bladder irrigation required until clearance of postoperative hematuria.
The study population will consist of 44 male patients diagnosed with BPH, presenting predominantly with obstructive lower urinary tract symptoms and having an indication for surgical treatment. Patients with a prostate with a large prostate, more than 50 g. . All eligible participants will undergo bipolar TURP as the definitive surgical intervention and will be randomly assigned to the study groups according to the predefined study protocol.
Evaluation of the Patients All eligible patients scheduled for bipolar transurethral resection of the prostate (TURP) will undergo a comprehensive preoperative assessment before enrollment in the study. The assessment will include detailed history taking, complete physical examination, laboratory investigations, and appropriate evaluation of the prostate and lower urinary tract symptoms. The collected clinical and demographic data will be recorded in a standardized manner for subsequent comparison between the two study groups.
Inclusion Criteria
Patients will be eligible for participation in the study if they fulfill the following criteria:
Patients will be excluded from the study if any of the following criteria are present:
42
Patient Assessment:
All individuals will be subjected to the following:
I. Preoperative Assessment:
A. Full history taking:
B. Complete physical examination:
C. Routine laboratory investigations:
- Complete blood cell (CBC).
D. Radiological examination:
Pelvic-abdominal ultrasonography will be done to assess prostate volume, post-voiding residual urine, and any bladder pathology.
E. Preoperative preparations of anticoagulant drugs: The most common practice before TURP is to discontinue all oral AC or AP therapy for a few days (2 to 5 days) prior to surgery and to preoperatively bridge with heparin or low-molecular-weight heparin (LMWH) therapy.
II. Surgical Procedure: All patients will undergo bipolar TURP in the lithotomy position under spinal anesthesia, unless contraindicated, after administration of a prophylactic antibiotic 1 hour before surgery.
Bipolar TURP will be performed using isotonic 0.9% sodium chloride irrigation. Homeostasis will be achieved throughout, with immediate cauterization of arterial and venous bleeding. Resected adenoma chips will be removed using an Ellik evacuator. A 3-way Foley catheter will be inserted, and continuous bladder irrigation will be maintained for 24 hours, stopping once the effluent became clear. Operative time and weight of resected tissue will be recorded. Intraoperative blood loss will be evaluated in terms of reduction in serum hemoglobin (Hb) and hematocrit (Hct) levels, which will measured before, immediately after surgery. The catheter will be removed on the 5th postoperative day unless bleeding persists. Antibiotics and analgesics will be administered as needed.
III. Postoperative Assessment:
Hemoglobin and hematocrit levels will be measured at 24 hours postoperatively. Irrigation fluid volume and time, hospital stay, and indwelling catheter duration will 44 be documented. Antibiotics and analgesics will be prescribed as needed. Postoperative complications such as clot retention, severe hematuria, need for reoperation, and other general complications will be recorded and managed. Follow-up will be scheduled at postoperative day 5-8 and 1 month, including bladder ultrasonography for postvoid residual volume and completion of the IPSS questionnaire.
Patients' Characteristics and Randomization Patients fulfilling the eligibility criteria will be randomly assigned into two parallel groups in a 1:1 allocation ratio. Randomization will be performed using an online randomization program, and each participant will be assigned a study code. The allocation sequence will be concealed using opaque sealed envelopes until the appropriate time of group assignment.
Group I (Dutasteride group): Patients allocated to this group will receive dutasteride 0.5 mg orally once daily for two weeks before bipolar TURP and will continue the treatment for two weeks postoperatively.
Group II (Control group): Patients assigned to the control group will receive matching placebo capsules once daily for two weeks before surgery and for two weeks following bipolar TURP.
The use of a matching placebo together with concealed randomization will allow the study to maintain its double-blinded randomized design and minimize potential bias during assessment of the study outcomes.
Sample Size The sample size was calculated using G-Power© software version 3.1.7 (Institute of Experimental Psychology, Heinrich Heine University, Dusseldorf, Germany), based on a previously published paper to show that the hemoglobin (Hb) and hematocrit (Hct) levels are significantly different from the null hypothesis value of 0.5 using a T-test, with an α-level of 0.05, a power of 85%, and an effect size of 0.985. The sample size was 20 cases in each group and was increased to avoid missing data by 10% to be nearly the total size of 22 cases in each group.
45 Bipolar TURP Equipment and Operative Team All surgical procedures were performed under standardized operative conditions in both study groups using the same Karl Storz bipolar resectoscope connected to a video-assisted system. To minimize variation related to surgical technique, the procedures were carried out by a team of three well-trained surgeons with comparable levels of surgical experience.
The equipment used for bipolar prostate resection consisted of the following components:
1. A 4-mm autoclavable telescope with a 30° direction of view, providing adequate visualization of the operative field.
2. An active working element used to facilitate manipulation and resection of the prostatic tissue.
3. An inner sheath equipped with a standard obturator. 4. A 26-Fr outer sheath fitted with two rotatable stopcocks to facilitate irrigation and drainage during the procedure.
5. Karl Storz bipolar electrodes are used for resection and coagulation of the prostatic tissue.
Using the same equipment and maintaining comparable surgical expertise in both groups helped ensure that differences in postoperative outcomes were not attributable to variations in the operative setting or surgeon experience.
Procedure • All patients included in the study received prophylactic antibiotic therapy with a third-generation cephalosporin approximately one hour before the scheduled operation.
47
, thereby minimizing the risk of postoperative urinary incontinence.
Postoperative Assessment and Follow-up Postoperative clinical and laboratory parameters were systematically recorded for all patients. Hemoglobin and hematocrit levels were assessed at one hour and 24 hours after surgery and compared with the corresponding preoperative measurements to evaluate the postoperative change in blood parameters.
The collected tissue fragments were subsequently prepared and submitted for histopathological examination.
Postoperatively, the urethral catheter was maintained until the urine became grossly clear, allowing discontinuation of continuous bladder irrigation. Longer catheterization was considered only when clinically indicated, such as in cases of bladder perforation or other circumstances requiring prolonged urinary drainage.
Before hospital discharge, the following postoperative parameters were documented:
After removal of the urethral catheter, the patient was observed until satisfactory spontaneous voiding was achieved. Post-voiding residual urine (PVR) was then assessed by ultrasonography to confirm adequate bladder emptying.
Follow-up
Postoperative follow-up visits were scheduled after surgery. During this visit, patients were assessed clinically and, when indicated, underwent:
This postoperative follow-up allowed assessment of the early recovery, urinary function, and symptomatic outcome following bipolar TURP
827 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
This study's planned enrollment of 44 is below the median of 92 across 626 interventional studies indexed under Prostatic Hyperplasia.
Browse Prostatic Hyperplasia studies →This is the only study on the registry with Mohamed Mahmoud Dogha as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1 - Male patients aged > 50 years. 2-Patients currently receiving oral anticoagulant or antiplatelet therapy. 3- Scheduled for bipolar TURP for symptomatic benign prostatic hyperplasia. 4-Prostate size > 50 g (measured by pelvi-abdominal or transrectal ultrasonography).
Exclusion Criteria:
Drug: Dutasteride 0.5 mg capsule orally once daily for 2 weeks preoperatively, followed by Bipolar TURP, and continued for 2 weeks postoperatively.
Drug: Dutasteride (0.5mg)
Drug: Matching placebo capsule orally once daily for 2 weeks preoperatively, followed by Bipolar TURP, and continued for 2 weeks postoperatively.
Drug: Placebo
Dutasteride 0.5 mg oral capsule (brand name Avodart; 0.5 mg daily for 2 weeks pre-op and 2 weeks post-op)
Identical physical appearance and dosing schedule matching the active drug arm (1 capsule daily for 2 weeks preoperatively, followed by Bipolar TURP, and continued for 2 weeks postoperatively).
Change in Hemoglobin (Hb) Level
Mean difference in serum Hb (g/dL) from baseline.
Time frame: Baseline (preoperative), immediately postoperatively, and 24 hours postoperatively.
Change in Hematocrit (Hct) Level
Mean difference in Hct from baseline.
Time frame: Baseline (preoperative), immediately postoperatively, and 24 hours postoperatively.
Total Volume of Bladder Irrigation Fluid
Total volume of 0.9% normal saline used (liters).
Time frame: Postoperative until 24 hrs.
Duration of Bladder Irrigation
Total time of continuous bladder irrigation (hours).
Time frame: Postoperative time: 24 hours.
Indwelling Catheterization Duration
Total duration of urethral catheterization (days).
Time frame: 5-8 day postoperative
Length of Hospital Stay
Postoperative hospital duration (days).
Time frame: From day of surgery to 7 days postoperative.
Incidence of Postoperative Complications
Rates of clot retention, severe hematuria requiring re-intervention, blood transfusion, or reoperation.
Time frame: Intraoperative through 1-month follow-up.
Symptomatic & Functional Improvements
Changes in International Prostate Symptom Score (IPSS) and Post-Void Residual (PVR) urine volume (mL).
Time frame: Baseline vs. 1-month postoperatively.
Plan to share: No — Individual participant data (IPD) will not be made publicly available in order to protect patient privacy and confidentiality, in accordance with the informed consent form approved by the Faculty of Medicine Research Ethics Committee, Fayoum University. De-identified aggregate outcome data and trial results will be published in peer-reviewed scientific journals.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.
Of 28 phase 4 interventional studies under Prostatic Hyperplasia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dutasteride